MLchartDataset catalogue

Scemblix

Term · Oncology and biomedicine · MLC-T-ONC-007574

A drug used to treat adults with chronic phase chronic myelogenous leukemia that is Philadelphia chromosome positive. It is used in patients whose cancer has the T315I mutation, whose cancer is newly diagnosed, or whose cancer was treated with at least two other tyrosine kinase inhibitors. It is also being studied in the treatment of other types of cancer. Scemblix blocks the BCR::ABL1 fusion protein, which may help keep cancer cells from growing and may kill them. Scemblix is a type of tyrosine kinase inhibitor. Also called asciminib hydrochloride.

Table 1. Record
IdentifierMLC-T-ONC-007574
FieldOncology and biomedicine
Synonymsasciminib hydrochloride
ReferencesNCI Dictionary of Cancer Terms
Record as JSON
{
  "id": "MLC-T-ONC-007574",
  "term": "Scemblix",
  "field": "Oncology and biomedicine",
  "definition": "A drug used to treat adults with chronic phase chronic myelogenous leukemia that is Philadelphia chromosome positive. It is used in patients whose cancer has the T315I mutation, whose cancer is newly diagnosed, or whose cancer was treated with at least two other tyrosine kinase inhibitors. It is also being studied in the treatment of other types of cancer. Scemblix blocks the BCR::ABL1 fusion protein, which may help keep cancer cells from growing and may kill them. Scemblix is a type of tyrosine kinase inhibitor. Also called asciminib hydrochloride.",
  "synonyms": [
    "asciminib hydrochloride"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms"
  ],
  "url": "https://mlchart.com/terminology/oncology/scemblix/"
}

Record 14,718 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.